ILC In Lung

Scope

This page is the beginner-facing guide to the ILC_in_lung wiki. It explains how to enter the field, what the main biological questions are, and which pages to read next when learning innate lymphoid cell biology in lung and airway disease.

The wiki emphasizes ILC2 and ILC3 biology in pulmonary inflammation, respiratory viral infection, tissue repair, stromal niches, neuroimmune regulation, metabolism, and disease-associated plasticity. It is a source-aware research map, not a complete textbook or clinical guideline.

Evidence Tags

#guide/beginner #axis/ILC_lung_homeostasis #axis/ILC_lung_infection #axis/ILC_airway_inflammation #axis/ILC_plasticity #tissue/lung #cell/ILC2 #cell/ILC3 #cell/ILC1

Beginner Mental Model

For a first pass, think of lung ILCs as tissue-positioned immune response modules. They do not use antigen-specific receptors like T cells and B cells, but they can rapidly sense epithelial, stromal, microbial, metabolic, and neural cues. Their output depends on subset, tissue compartment, activation state, disease trigger, and timing.

Subset	Simplest Starting Idea	Lung Disease Meaning	Main Caution
ILC2	Type 2 and repair-capable ILCs	Allergic airway inflammation, viral AHR, epithelial repair, stromal niche feedback, neuroimmune regulation	ILC2s can be pathogenic, reparative, memory-like, or plastic depending on context
ILC3	IL-22/IL-17-capable ILCs	Bacterial defense, neonatal lung niches, ARDS-like injury, neutrophilic and steroid-resistant asthma	IL-17-producing ILC-like cells require careful marker and lineage interpretation
ILC1/NK-like states	Type 1 inflammatory or cytotoxic-adjacent programs	Important for plasticity, infection, tumor, and mixed inflammation interpretation	Do not merge ILC1, NK cells, and ILC2-to-ILC1-like states without source-specific evidence

First Reading Path

Start with ILC Research Trend From Then To Now to understand how the field moved from ILC discovery to lung disease mechanisms.
Read Lung ILC Core Evidence Synthesis for the current integrated map across ILC2 and ILC3.
Open ILC2 and ILC3 as entity hubs when you want cell-specific claims.
Use the disease pages when the question is about pathology: ILC2 Roles In Pulmonary Disease and ILC3 Roles In Pulmonary Disease.
Use the regulation pages when the question is mechanistic: ILC2 Functional Regulation Mechanisms and ILC3 Functional Regulation Mechanisms.
Use ILC Regulation Of Adaptive Immunity when the question is how ILCs shape T cells, B cells, or Tregs; keep lung-direct and gut/tonsil evidence separated.
Go to source notes only when you need citation traceability, model details, or claim-level confidence boundaries.

Concept Map

flowchart TB
    accTitle: Lung ILC Beginner Map
    accDescr: A beginner-oriented map showing how to enter the ILC-in-lung wiki through history, core synthesis, cell hubs, disease topics, mechanism topics, and source notes.

    start["Start here<br/>ILC in lung guide"] --> history["Field history"]
    start --> core["Core synthesis<br/>current model"]
    core --> ilc2["ILC2 hub<br/>type 2 and repair"]
    core --> ilc3["ILC3 hub<br/>IL-22 and IL-17"]
    ilc2 --> ilc2_disease["ILC2 disease roles"]
    ilc2 --> ilc2_reg["ILC2 regulation mechanisms"]
    ilc3 --> ilc3_disease["ILC3 disease roles"]
    ilc3 --> ilc3_reg["ILC3 regulation mechanisms"]
    ilc2_disease --> sources["Source notes<br/>claim traceability"]
    ilc2_reg --> sources
    ilc3_disease --> sources
    ilc3_reg --> sources

    classDef start_class fill:#e8f3ff,stroke:#3b6ea8,stroke-width:2px,color:#17324d
    classDef synthesis_class fill:#eef7ed,stroke:#4d8a50,stroke-width:2px,color:#173d1d
    classDef cell_class fill:#fff4de,stroke:#b47a1f,stroke-width:2px,color:#4a3108
    classDef topic_class fill:#f6eefc,stroke:#7a55a3,stroke-width:2px,color:#2d1645
    classDef source_class fill:#f4f4f4,stroke:#777,stroke-width:1px,color:#222

    class start start_class
    class history,core synthesis_class
    class ilc2,ilc3 cell_class
    class ilc2_disease,ilc2_reg,ilc3_disease,ilc3_reg topic_class
    class sources source_class

Core Biological Threads

1. ILC2s: Allergic Pathology, Repair, And Niche Regulation

The ILC2 source set is strongest around asthma and allergic airway inflammation, respiratory viral infection, post-viral repair, metabolic regulation, neuroimmune regulation, tissue niches, and plasticity. ILC2s often amplify type 2 inflammation through IL-5 and IL-13, but they can also support epithelial repair through amphiregulin-associated programs and participate in stromal or macrophage niche remodeling.

Spatial and regulatory evidence adds an important layer: lung ILC2s can sit in adventitial/peribronchovascular niches supported by IL-33/TSLP-producing stromal cells, while IFN-gamma can suppress ILC2 function or constrain type 2 lymphocyte movement during mixed inflammation. These claims are organized primarily in ILC2, with disease and mechanism expansion in ILC2 Roles In Pulmonary Disease, ILC2 Functional Regulation Mechanisms, and Lung ILC Core Evidence Synthesis.

2. ILC3s: Defense, IL-17 Inflammation, And Severe Asthma Branches

The ILC3 source set spans mucosal protection, lung IL-22 responses during bacterial infection, developmental lung niches, ARDS/IL-17A, neutrophilic airway inflammation, steroid-resistant asthma, fibroblast SCF/KIT licensing, and IL-17 classification boundaries. In this wiki, ILC3s should not be labeled simply as protective or pathogenic. Their role depends on whether the relevant output is IL-22 barrier defense, IL-17A/neutrophilic inflammation, chemokine production, or stromal crosstalk.

3. Plasticity Is A Feature, Not A Footnote

ILC subset labels are useful but incomplete. ILC2s can acquire memory-like behavior, become ILC1-like under COPD-associated inflammatory pressure, or show IL-17-producing ILC2/ILC3-like boundary states. ILC3s can also show state changes linked to smoking, steroid resistance, tissue stress, and transcriptional remodeling. Any serious claim should preserve marker set, tissue compartment, species, disease model, and assay type.

4. Adaptive Immunity Is A Cross-Subset Interface

ILCs do not use antigen-specific receptors, but selected ILC states can still regulate adaptive immunity. The strongest lung-direct examples in this source set are IL-33/ST2-linked ILC2 PD-L1 promotion of Th2 polarization, ILC2 OX40L licensing of local Th2/Treg expansion, and ILC2-supported Gata3high Treg feedback that limits effector-memory Th2 expansion in mouse type 2 inflammation. ILC3 evidence is richer in gut and mucosal lymphoid tissues: MHCII, IL-2, alphaV integrin, CD40L, BAFF, IL-15, STING, GM-CSF-myeloid crosstalk, and CTLA-4 support adaptive-tolerance framing, while RANKL/RANK, circadian timing, FFAR2, VIP circuits, trained defense, and HB-EGF broaden the adjacent barrier-defense and tissue-protection context. For a focused map, see ILC Regulation Of Adaptive Immunity.

5. Evidence Type Matters

Mouse perturbation studies are usually strongest for causality. Human lung tissue, sputum, blood, nasal airway, and scRNA-seq studies are essential for relevance but often have different inferential limits. Reviews are useful for conceptual framing, but primary source notes should anchor mechanistic claims.

How To Use Claim Confidence

Confidence	How To Interpret It
High confidence	Source-specific claim is directly supported by the paper's model, assay, and outcome
Medium-high confidence	Mechanism is experimentally supported but translation, tissue generality, or disease breadth needs labels
Medium confidence	Useful working model or cross-source synthesis, but details require source-level checking
Low confidence	Hypothesis, review-level extrapolation, or claim that should not be reused without additional evidence

Common Beginner Mistakes To Avoid

Do not treat ILC2 activation as automatically bad; ILC2s can drive airway disease or support repair depending on context.
Do not treat ILC3 as only a gut cell; this wiki includes lung ILC3 evidence in infection, development, ARDS-like injury, and severe asthma.
Do not merge mouse lung, human sputum, human blood, and nasal-polyp findings without stating the compartment.
Do not assume IL-17-producing ILC-like cells are always canonical ILC3s; some sources support ILC2/ILC3-like boundary states.

Page Map

Question	Best Page
How did the field evolve?	ILC Research Trend From Then To Now
What is the overall story?	Lung ILC Core Evidence Synthesis
What do ILC2s do in lung disease?	ILC2 Roles In Pulmonary Disease
What regulates ILC2 function?	ILC2 Functional Regulation Mechanisms
What do ILC3s do in lung disease?	ILC3 Roles In Pulmonary Disease
What regulates ILC3 function?	ILC3 Functional Regulation Mechanisms
How do ILCs regulate adaptive immunity?	ILC Regulation Of Adaptive Immunity

| Which claims are citation-ready? | Source pages marked as source-reviewed evidence notes |

Open Questions

Which ILC mechanisms are conserved between mouse allergic airway models and human asthma endotypes?
When do respiratory viruses induce pathogenic ILC2-driven AHR versus protective ILC2-mediated repair?
Which IL-17-producing ILC populations in lung disease are bona fide ILC3s, plastic ILC2-derived states, or mixed-gate populations?
How do gut microbiome state, fungal sensing, and cytokine-conditioned ILC plasticity reshape lung type 3 inflammation across HP, fungal infection, severe asthma, and ARDS-like contexts?
In severe asthma, how should sex, blood-versus-sputum compartment, and biologic therapy status be preserved when interpreting ILC2/ILC3 abundance or cytokine output?
Which evidence layer should be prioritized next: human BAL, bronchial biopsy, sputum, lung scRNA-seq, spatial data, or perturbation models?

Wiki Status

The local source library currently contains 150 processed references, with 150 source pages promoted to focused manual crystallization mode and 0 retained as provisional bulk-ingest mode.
Focused source pages are the preferred evidence layer for reusable biological claims because they include model context, assay directness, claim-level confidence, and caveats.
Provisional source pages are useful for routing and triage, but their biological claims should be manually checked before being reused in manuscripts, figures, grant text, or durable synthesis.
Batch provenance belongs in audit and log pages; digest, topic, and entity pages should read as biology-first knowledge nodes.